Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. The university aims to identify treatments for life-threatening anti-microbial diseases and metabolic disorders.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

The Pharma Data

AUGUST 13, 2020

It is the only biologic approved which is designed to target and block immunoglobin E (IgE) for the treatment of moderate-to-severe persistent allergic asthma and chronic idiopathic urticaria (CIU). Approximately 460,000 patients in the US have been treated with Xolair since its first approval for allergic asthma back in 2003.

FDA 52

FDA Clinical Development Treatment Therapies 52

The Pharma Data

APRIL 14, 2021

Xolair for self-injection offers healthcare providers and appr opriate patients another administration option for more flexibility in managing their treatment. Roche’s Chief Medical Officer and Head of Global Product Development. with Xolair since its initial approval in 2003. today announced that the U.S. indications.

FDA Approval 52

FDA Approval Clinical Development FDA Licensing 52

The Pharma Data

NOVEMBER 5, 2020

Velders is presently chairman of HollandBIO, the association of Dutch biotech companies, and provides years of experience, specifically in the cell and gene therapy areas. acousia Therapeutics – Jonas Dyhrfjeld-Johnsen joined Germany-based Acousia in the new role of chief development officer. from 1993 to 1995. Dillon is a former St.

Analytical Chemistry 40

Analytical Chemistry Pharmaceuticals Small Molecule Therapies 40

Drug Target Review

NOVEMBER 30, 2023

On my return to Europe, I took a position at Nestlé as Head of the Research Centre, where I led the scientific development of several highly innovative health promoting food products from laboratory to market. Then I was approached to co-found AC Immune in 2003. My family and friends said I was crazy to take this step.

Disease 95

Disease Laboratories Therapies Treatment 95

Agency IQ

SEPTEMBER 15, 2023

developing or amending a monograph) or sponsor-initiated operations (e.g., Background on oral phenylephrine as a nonprescription nasal decongestant Phenylephrine is an alpha-1 adrenergic agonist that is approved as a nonprescription oral treatment for temporary relief of nasal congestion , sinus congestion and pressure.

Science 40

Science FDA Clinical Trials Pharmacy 40

The Pharma Data

FEBRUARY 25, 2021

5 Currently there is no cure or treatment for TBE, only management of symptoms. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme.

FDA 52

FDA Vaccine Virus Clinical Trials 52